38 research outputs found
Ceres Scales Ground Validation Campaigns for Gerb. Assessment of the Valencia Anchor Station Capabilities
Proceedings del 3rd MSG RAO Workshop, celebrado el 15 de junio de 2006 en Helsinki, Finlandia.The Valencia Anchor Station (VAS) was set up by the
University of Valencia at the natural region of UtielRequena Plateau in 2001. The plateau is a large and
reasonably homogeneous area suitable for validation of
low spatial resolution satellite data and products such
as GERB's. In the framework of the EUMETSAT/ESA
MSG-RAO Project no. 138 GIST Proposal for
Calibration/Validation of SEVIRI and GERB, and of
the Spanish Research Programme on Space Project
SCALES (SEVIRI & GERB Cal/Val Area for Largescale Field ExperimentS), three GERB ground
validation campaigns have so far been carried out at the
VAS under different land surface conditions. CERES
instruments onboard NASA EOS Aqua and Terra
satellites, operating in PAPS (Programmable Azimuth
Plane Scanning) mode, have generously provided
additional SW and LW radiance measurements to
support validation efforts. These have shown to be
most valuable as intermediate validation step between
ground measurements and the large GERB pixel size
study protocol
Funding Information: AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019–2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017–003288-36), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019–002992-33). Funding Information: The FAITH project is funded under the European Commission (EC) Horizon Europe Programme, ‘H2020-EU.3.1.—SOCIETAL CHALLENGES—Health, demographic change, and well-being’. It is funded to the value €4.8 M, under the specific topic ‘SC1-DTH-01–2019—Big data and Artificial Intelligence for monitoring health status and quality of life after the cancer treatment’ with Grant agreement ID: 875358. The funder has no influence in the design, collection, analysis, data interpretation, or manuscript writing. Funding Information: RL is supported by an individual Scientific Employment Stimulus from Fundação para a Ciência e Tecnologia, Portugal (CEECIND/04157/2018). Publisher Copyright: © 2022, The Author(s).Background: Depression is a common condition among cancer patients, across several points in the disease trajectory. Although presenting higher prevalence rates than the general population, it is often not reported or remains unnoticed. Moreover, somatic symptoms of depression are common in the oncological context and should not be dismissed as a general symptom of cancer. It becomes even more challenging to track psychological distress in the period after the treatment, where connection with the healthcare system typically becomes sporadic. The main goal of the FAITH project is to remotely identify and predict depressive symptoms in cancer survivors, based on a federated machine learning (ML) approach, towards optimization of privacy. Methods: FAITH will remotely analyse depression markers, predicting their negative trends. These markers will be treated in distinct categories, namely nutrition, sleep, activity and voice, assessed in part through wearable technologies. The study will include 300 patients who have had a previous diagnosis of breast or lung cancer and will be recruited 1 to 5 years after the end of primary cancer. The study will be organized as a 12-month longitudinal prospective observational cohort study, with monthly assessments to evaluate depression symptoms and quality of life among cancer survivors. The primary endpoint is the severity of depressive symptoms as measured by the Hamilton Depression Rating Scale (Ham-D) at months 3, 6, 9 and 12. Secondary outcomes include self-reported anxiety and depression symptoms (HADS scale), and perceived quality of life (EORTC questionnaires), at baseline and monthly. Based on the predictive models gathered during the study, FAITH will also aim at further developing a conceptual federated learning framework, enabling to build machine learning models for the prediction and monitoring of depression without direct access to user’s personal data. Discussion: Improvements in the objectivity of psychiatric assessment are necessary. Wearable technologies can provide potential indicators of depression and anxiety and be used for biofeedback. If the FAITH application is effective, it will provide healthcare systems with a novel and innovative method to screen depressive symptoms in oncological settings. Trial registration: Trial ID: ISRCTN10423782. Date registered: 21/03/2022.publishersversionpublishe
A prospective observational study for a Federated Artificial Intelligence solution for monitoring mental health status after cancer treatment (FAITH): study protocol
Background: Depression is a common condition among cancer patients, across several points in the disease trajec‑
tory. Although presenting higher prevalence rates than the general population, it is often not reported or remains
unnoticed. Moreover, somatic symptoms of depression are common in the oncological context and should not be
dismissed as a general symptom of cancer. It becomes even more challenging to track psychological distress in the
period after the treatment, where connection with the healthcare system typically becomes sporadic. The main goal
of the FAITH project is to remotely identify and predict depressive symptoms in cancer survivors, based on a federated
machine learning (ML) approach, towards optimization of privacy.
Methods: FAITH will remotely analyse depression markers, predicting their negative trends. These markers will be
treated in distinct categories, namely nutrition, sleep, activity and voice, assessed in part through wearable technolo‑
gies. The study will include 300 patients who have had a previous diagnosis of breast or lung cancer and will be
recruited 1 to 5 years after the end of primary cancer. The study will be organized as a 12-month longitudinal pro‑
spective observational cohort study, with monthly assessments to evaluate depression symptoms and quality of life
among cancer survivors. The primary endpoint is the severity of depressive symptoms as measured by the Hamilton
Depression Rating Scale (Ham-D) at months 3, 6, 9 and 12. Secondary outcomes include self-reported anxiety and
depression symptoms (HADS scale), and perceived quality of life (EORTC questionnaires), at baseline and monthly.
Based on the predictive models gathered during the study, FAITH will also aim at further developing a conceptual fed‑
erated learning framework, enabling to build machine learning models for the prediction and monitoring of depres‑
sion without direct access to user’s personal data.
Discussion: Improvements in the objectivity of psychiatric assessment are necessary. Wearable technologies can
provide potential indicators of depression and anxiety and be used for biofeedback. If the FAITH application isinfo:eu-repo/semantics/publishedVersio
Breast cancer PAM50 signature: Correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
Background: Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular. Results: The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80. Conclusions: In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method
Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series
[Background]: Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular.[Results]: The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80.[Conclusions]: In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method.M.M was supported by two research grants from Ministry of Economy and Competitiveness ISCIII-FIS grants (PI 12/02684): “Predictores genómicos de respuesta a la quimioterapia neoadyuvante con docetaxel-carboplatino en pacientes con cáncer de mama triple negativo”/“Genomic predictors of response to neoadjuvant chemotherapy with docetaxel-carboplatin in patients with triple negative breast cancer”; and (PI 15/00117): “Cáncer de mama triple negative: Predicción de respuesta a docetaxel-carboplatino neoadyuvante mediante caracterización de TILs y firmas inmunes basadas en secuenciación masiva de RNA”/” Triple negative breast cancer: Prediction of response to neoadjuvant docetaxel-carboplatin by characterization of TILs and immune signatures based on massive RNA sequencing”. C.M.P was supported by funds from the NCI Breast SPORE program (P50-CA58223).Peer reviewe
GEICAM Guidelines for the Management of Patients with Breast Cancer During the COVID-19 Pandemic in Spain
Breast cancer (BC) is the most common cancer in women in
Spain. During the COVID-19 pandemic caused by the SARSCoV-2 virus, patients with BC still require timely treatment
and follow-up; however, hospitals are overwhelmed with
infected patients and, if exposed, patients with BC are at
higher risk for infection and serious complications if infected.
Thus, health care providers need to evaluate each BC treatment and in-hospital visit to minimize pandemic-associated
risks while maintaining adequate treatment efficacy. Here we
present a set of guidelines regarding available options for BC
patient management and treatment by BC subtype in the
context of the COVID-19 pandemic. Owing to the lack of evidence about COVID-19 infection, these recommendations
are mainly based on expert opinion, medical organizations’
and societies’ recommendations, and some published evidence. We consider this a useful tool to facilitate medical
decision making in this health crisis situation we are facing
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
Purpose: To determine the frequency of breast cancer (BC) patients with hereditary risk features in a wide retrospective cohort of patients in Spain. Methods: a retrospective analysis was conducted from 10, 638 BC patients diagnosed between 1998 and 2001 in the GEICAM registry “El Álamo III”, dividing them into four groups according to modified ESMO and SEOM hereditary cancer risk criteria: Sporadic breast cancer group (R0); Individual risk group (IR); Familial risk group (FR); Individual and familial risk group (IFR) with both individual and familial risk criteria. Results: 7, 641 patients were evaluable. Of them, 2, 252 patients (29.5%) had at least one hereditary risk criteria, being subclassified in: FR 1.105 (14.5%), IR 970 (12.7%), IFR 177 (2.3%). There was a higher frequency of newly diagnosed metastatic patients in the IR group (5.1% vs 3.2%, p = 0.02). In contrast, in RO were lower proportion of big tumors (> T2) (43.8% vs 47.4%, p = 0.023), nodal involvement (43.4% vs 48.1%, p = 0.004) and lower histological grades (20.9% G3 for the R0 vs 29.8%) when compared to patients with any risk criteria. Conclusions: Almost three out of ten BC patients have at least one hereditary risk cancer feature that would warrant further genetic counseling. Patients with hereditary cancer risk seems to be diagnosed with worse prognosis factors
Mecanismos de coordinación docente en la Facultad de Derecho
El trabajo de esta Red docente ha consistido en recopilar y proponer nuevos mecanismos de coordinación docente aplicables a las cuatro titulaciones de Grado de la Facultad de Derecho. Los resultados de los Informes de Seguimiento de cada titulación de la Facultad, muestran la necesidad de establecer instrumentos de coordinación del profesorado de cada titulación para unificar y armonizar criterios en lo relativo al volumen total del trabajo exigido al estudiante, la distribución temporal adecuada del mismo y el trabajo colectivo de todos los profesores para conseguir los objetivos plasmados en la Memoria Verificada por ANECA para cada título. El objetivo de esta Red ha sido recopilar los mecanismos de coordinación ya existentes y proponer otros nuevos que puedan plantearse en las correspondientes Comisiones de titulación y aplicarse en cursos sucesivos en nuestra Facultad
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC